New hope for AML patients: gentler drug combo could replace harsh chemo
NCT ID NCT07664839
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a new drug combination (venetoclax plus azacitidine) against standard chemotherapy for adults with a specific type of acute myeloid leukemia (AML) that has NPM1 or IDH mutations. About 148 people will be randomly assigned to one of the two treatments. The main goal is to see if the new combo works as well as standard chemo at achieving remission, while also tracking side effects and long-term outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Venetoclax combined with azacitidine
What this could lead to
If it works, this could offer a less intensive treatment option for certain AML patients, potentially with fewer side effects than standard chemotherapy.
What could go wrong
This is a phase 2 trial with only 148 participants, so results are preliminary. The new regimen may not be as effective as standard chemo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDH1 MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••